Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3…

Overview of attention for article published in Lancet Oncology, April 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 7 news outlets
twitter: 92 X users

guideline: 5 clinical guideline sources

Readers on

mendeley: 155 Mendeley

So far, Altmetric has seen 102 X posts from 92 X users, with an upper bound of 215,720 followers.

RT @drkpavithran: No OS benefit for adjuvant Pacli/carbo chemotherapy given after standard cisplatin-based CTRT for unselected locally adva…

RT @radioncol: #ASCO21 で NEGATIVE studyと発表されていた #cervicalcancer のCRT後chemo (CBDCA+PTX) vs. CRTの論文化。

(´・ω・｀)ｼｮﾎﾞｰﾝ

RT @TheLancetOncol: ICYMI: In the OUTBACK ph 3 trial of adjuvant chemotherapy after chemoradiotherapy for locally advanced cervical cancer,…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 98 additional X posts.